Lin stated, "we remain on track to complete the [DRAGON] study in Q4 this year." Lin shared, "the FDA recommended that we complete the 24-month study, which we are about to complete coming up in ...
Parallel Bio, a biotech company pioneering human-first drug discovery, today announced it has raised $21 million Series A funding, led by AIX Ventures. The round attracted prominent leaders in AI and ...
Use of Non-GAAP Financial Measures: This press release contains financial measures that have not been calculated in accordance with accounting principles generally accepted in the U.S. (GAAP). We ...